Takeda brings a deep appreciation for the global burden of digestive diseases and a personal understanding not only of the significant unmet clinical needs, but of the unmet human needs. It’s why for more than 25 years, Takeda, and our collaboration partners, have worked to improve the lives of patients through innovative therapies and dedicated patient support programs. It’s also the reason we’re focused on areas of gastroenterology associated with serious unmet needs like inflammatory bowel disease, immune-related diseases, liver, and motility disorders. Despite advances that have been made, there is still so much more to be done. In many ways, we’re just getting started. Takeda is committed to making a meaningful difference in the lives of those living with GI diseases.
GATTEX® (teduglutide) for injection is indicated for the treatment of adults and pediatric patients 1 year of age and older with short bowel syndrome (SBS) who are dependent on parenteral support.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
GATTEX has been associated with acceleration of neoplastic growth, intestinal obstruction, biliary and pancreatic disease, fluid imbalance and fluid overload, and increased absorption of concomitant oral medication.
